Effect of herbal drug Terminalia chebula, Commiphora myrrh and Commiphora mukul mixture on diabetes in patients with hyperlipidemia .

Evaluation of effect of Terminalia chebula fruit, Commiphora myrrh and Commiphora mukul oleo-gum-resin mixture on glycemic control and lipid profile in type 2 diabetic patients with hyperlipidemia: A double blind, randomized, placebo controlled clinical trial.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201307011157N8

Enrollment

Registered

2015-03-08

Start date

2015-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetes. Condition 2: Added at 2015-07-20: Mixed hyperlipidaemia. Non-insulin-dependent diabetes mellitus Added at 2015-07-20: Hypercholesterolaemia with endogenous hyperglyceridaemia and Hyperlipidaemia, group C

Interventions

Intervention 1: Intervention group: 600 mg herbal drug capsule is administered 3 times a day orally for 3 months. Intervention 2: Placebo group: 600 mg placebo capsule is administered 3 times a day fo

Treatment - Drugs

Intervention group: 600 mg herbal drug capsule is administered 3 times a day orally for 3 months

Placebo group: 600 mg placebo capsule is administered 3 times a day for 3 months.

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Iranian type 2 diabetic patients; aged 40 to 60 years; fasting blood glucose levels from 150 to 180 mg/dL; blood glycosylated hemoglobin levels from 7.5 to 8.5 percent; LDL-c > 100 mg/dL; triglyceride >150 mg/dL; oral intake of not more than 10 mg glyburide and 1000 mg metformin at maximum. Exclusion criteria: Patients receiving insulin therapy; patients with cardiao vascular, renal, hepatic, hematological, hypothyroidism, vertigo and seizure diseases; patients with a history of gallstones or gall bladder surgery; patients under estrogen, steroid, beta-blocker and thiazide therapy; pregnant women; women planning for pregnancy; breast-feeding women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level will be determined in laboratory by commercial standard kit.;Glycosylated hemoglobin (HbA1c). Timepoint: At starting of the study and after 3 months. Method of measurement: HbA1c percent will be determined in laboratory by commercial standard kit.	—

Secondary

Measure	Time frame
Triglyceride. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood triglyceride level will be determined in laboratory by commercial standard kit.;High-density lipoprotein (HDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood HDL level will be determined in laboratory by commercial standard kit.;Aspartate aminotransferase (AST). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood AST level will be determined in laboratory by commercial standard kit.;Alanine transaminase (ALT). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood ALT level will be determined in laboratory by commercial standard kit.;Blood urea nitrogen (BUN). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood BUN level will be determined in laboratory by commercial standard kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level will be determined in laboratory by commercial standard kit.;Cholesterol. Timepoint: At starting of the study and after3 months. Method of measurement: Blood cholesterol level will be determined in laboratory by commercial standard kit.;Low-density lipoprotein (LDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood LDL level will be determined in laboratory by commercial standard kit.	—

Measure

Time frame

Triglyceride. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood triglyceride level will be determined in laboratory by commercial standard kit.;High-density lipoprotein (HDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood HDL level will be determined in laboratory by commercial standard kit.;Aspartate aminotransferase (AST). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood AST level will be determined in laboratory by commercial standard kit.;Alanine transaminase (ALT). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood ALT level will be determined in laboratory by commercial standard kit.;Blood urea nitrogen (BUN). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood BUN level will be determined in laboratory by commercial standard kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level will be determined in laboratory by commercial standard kit.;Cholesterol. Timepoint: At starting of the study and after3 months. Method of measurement: Blood cholesterol level will be determined in laboratory by commercial standard kit.;Low-density lipoprotein (LDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood LDL level will be determined in laboratory by commercial standard kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Fallah Huseini

Institute of Medicinal Plants

huseini_fallah@yahoo.com+98 26 3476 4021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026